Chakraborty Avirup, Patil Krishna, Dasgupta Sanjay, Tarafdar Abhijit, Chakrabarti Sekhar, Chakraborty Nilanjan
Virology Department, ICMR Virus Unit, Kolkata, India.
BMJ Case Rep. 2012 Apr 2;2012:bcr1220115314. doi: 10.1136/bcr.12.2011.5314.
The authors report a case of a 47-year-old cytomegalovirus (CMV) immunoglobulin G (IgG) seropositive male patient with end stage renal disease who received a live renal transplant from a CMV IgG seropositive donor. Six months post-transplantation, the patient presented with reduced renal allograft function associated with fever, severe breathlessness, new onset jaundice and pancytopenia. His CMV DNA PCR came positive. Hepatitis C virus (HCV) RNA PCR also came positive (genotype I) though anti-HCV test performed before and after transplantation was negative. The patient was treated with oral valganciclovir and showed improvement of his clinical condition and was subsequently discharged under supervised therapy. However, the patient could not be treated for HCV because of risk of renal allograft rejection. The authors suggest oral valganciclovir for management of CMV infection and proper detection and eradication of HCV before renal transplantation to avoid future complications and prolongation of allograft survival.
作者报告了一例47岁的巨细胞病毒(CMV)免疫球蛋白G(IgG)血清学阳性的男性终末期肾病患者,该患者接受了来自CMV IgG血清学阳性供体的活体肾移植。移植后6个月,患者出现移植肾功能减退,伴有发热、严重呼吸困难、新发黄疸和全血细胞减少。他的CMV DNA聚合酶链反应(PCR)呈阳性。丙型肝炎病毒(HCV)RNA PCR也呈阳性(I型基因型),尽管移植前后进行的抗HCV检测均为阴性。患者接受了口服缬更昔洛韦治疗,临床状况有所改善,随后在监督治疗下出院。然而,由于存在肾移植排斥风险,该患者无法接受HCV治疗。作者建议使用口服缬更昔洛韦治疗CMV感染,并在肾移植前对HCV进行适当检测和根除,以避免未来并发症并延长移植肾存活时间。